Loading...
Failure-Free Survival and Radiotherapy in Patients With Newly Diagnosed Nonmetastatic Prostate Cancer
James, Nicholas D. Spears, Melissa R. Clarke, Noel W. Dearnaley, David P. Mason, Malcolm D. Parker, Christopher C. Ritchie, Alastair W. S. Russell, J. Martin Schiavone, Francesca Attard, Gerhardt
James, Nicholas D.
Spears, Melissa R.
Clarke, Noel W.
Dearnaley, David P.
Mason, Malcolm D.
Parker, Christopher C.
Ritchie, Alastair W. S.
Russell, J. Martin
Schiavone, Francesca
Attard, Gerhardt
Authors
James, Nicholas D.
Spears, Melissa R.
Clarke, Noel W.
Dearnaley, David P.
Mason, Malcolm D.
Parker, Christopher C.
Ritchie, Alastair W. S.
Russell, J. Martin
Schiavone, Francesca
Attard, Gerhardt
de Bono, Johann S.
Birtle, Alison
Engeler, Daniel S.
Elliott, Tony
Matheson, David
O’Sullivan, Joe
Pudney, Delia
Srihari, Narayanan
Wallace, Jan
Barber, Jim
Syndikus, Isabel
Parmar, Mahesh K. B.
Sydes, Matthew R.
Spears, Melissa R.
Clarke, Noel W.
Dearnaley, David P.
Mason, Malcolm D.
Parker, Christopher C.
Ritchie, Alastair W. S.
Russell, J. Martin
Schiavone, Francesca
Attard, Gerhardt
de Bono, Johann S.
Birtle, Alison
Engeler, Daniel S.
Elliott, Tony
Matheson, David
O’Sullivan, Joe
Pudney, Delia
Srihari, Narayanan
Wallace, Jan
Barber, Jim
Syndikus, Isabel
Parmar, Mahesh K. B.
Sydes, Matthew R.
Editors
Other contributors
Affiliation
Epub Date
Issue Date
2016-11-25
Submitted date
Alternative
Abstract
Citation
Failure-Free Survival and Radiotherapy in Patients With Newly Diagnosed Nonmetastatic Prostate Cancer 2016, 2 (3):348 JAMA Oncology
Publisher
Journal
Research Unit
PubMed ID
PubMed Central ID
Embedded videos
Type
Journal article
Language
en
Description
Series/Report no.
ISSN
2374-2437
EISSN
ISBN
ISMN
Gov't Doc #
Sponsors
The Medical Research Council sponsored the study and was involved in the design and conduct of the study; collection, management, analysis, and interpretation of the data; and preparation, review, and approval of the manuscript. Funding was also provided by Cancer Research UK, Astellas, Janssen, Novartis, Sanofi-Aventis, and Pfizer, none of which were directly involved in the research.